2639 Results

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Noy
    Noy
  5. Moskowitz
    Moskowitz
  6. Younes
    Younes
  7. Matasar
    Matasar
  8. Moskowitz
    Moskowitz
  9. Yahalom
    Yahalom
  10. Portlock
    Portlock

Groups

  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)
  7. Executive Committee, Center for Hematologic Malignancies (389)
  8. Epidemiology and Biostatistics (363)
  9. GSK Faculty (356)
  10. Department of Pathology and Laboratory Medicine (300)
  1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Metabolic regulation of the cancer-immunity cycle
    Editorial

    Somarribas Patterson, L. F.; Vardhana, S. A.
    Trends in Immunology (2021)

    Fulltext@MSK | Save
  • Feasibility of combining the phosphatidylinositol 3-kinase inhibitor copanlisib with rituximab-based immunochemotherapy in patients with relapsed indolent B-cell lymphoma
    Journal Article

    Matasar, M. J.; Dreyling, M.; Leppä, S.; Santoro, A.; Pedersen, M.; Buvaylo, V.; Fletcher, M.; Childs, B. H.; Zinzani, P. L.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Remission of a primary effusion lymphoma with initiation of highly active antiretroviral therapy and antiviral therapy in a previously untreated HIV-positive patient
    Journal Article

    Musinsky, J.; Noy, A.
    HIV and AIDS Review (2021)

    Fulltext@MSK | Save
  • Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: Is 4 Gy suitable for curable patients?
    Journal Article

    Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Casey, D. L.; Yang, J. C.; Wijentunga, N. A.; Shepherd, A.; Hajj, C.; Qi, S.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the phase III CHRONOS-3 trial
    Meeting Abstract

    Özcan, M.; Jin, J.; Szomor, Á.; Panayiotidis, P.; Yoon, D. H.; Tyczynska, A. M.; Mongay Soler, L.; Cao, A.; Hiemeyer, F.; Childs, B. H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Updates in therapies of relapsed and refractory follicular lymphoma [Interview]
    Miscellaneous

    Batlevi, C. L.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • Outcomes of adult T-cell leukemia/lymphoma with allogeneic stem cell transplantation: Single-institution experience
    Journal Article

    Epstein-Peterson, Z. D.; Ganesan, N.; Barker, J. N.; Drullinsky, P. R.; Ghione, P.; Jakubowski, A. A.; Kumar, A.; Moskowitz, A. J.; Noy, A.; Perales, M. A.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials
    Journal Article

    Palomba, M. L.; Jun, M. P.; Lymp, J.; Nguyen, A.; McGarvey, N.; Gitlin, M.; Pelletier, C.; Keating, S. J.; Godwin, J.
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: Report of a phase 2 trial and exploratory biomarker analyses
    Journal Article

    Landsburg, D. J.; Barta, S. K.; Ramchandren, R.; Batlevi, C.; Iyer, S.; Kelly, K.; Micallef, I. N.; Smith, S. M.; Stevens, D. A.; Alvarez, M.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save